Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin in Child-Pugh B Cirrhosis
NCT02271295Phase 3Suspended
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2015
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in Cirrhosis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Morbidity and mortality at 24 months. Started Jul 2015; status: suspended.
02
Drugs
enoxaparin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT02271295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271295.